Signaling to the Ribosome in Cancer-It Is More Than Just mTORC1

被引:34
作者
Hannan, Katherine M. [1 ]
Sanij, Elaine [1 ,2 ]
Hein, Nadine [1 ]
Hannan, Ross D. [1 ,3 ,4 ]
Pearson, Richard B. [1 ,3 ,4 ]
机构
[1] Peter MacCallum Canc Ctr, Growth Control & Differentiat Program, Melbourne, Vic, Australia
[2] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia
[3] Univ Melbourne, Dept Biochem & Mol Biol, Melbourne, Vic, Australia
[4] Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic 3004, Australia
基金
英国医学研究理事会;
关键词
PI3K/AKT/mTORC1; ribosome; cancer; protein synthesis; RNA-POLYMERASE-I; PROTEIN-SYNTHESIS; C-MYC; MESSENGER-RNA; S6; KINASE; TRANSLATIONAL CONTROL; CARDIAC MYOCYTES; MAMMALIAN TARGET; CELL-GROWTH; CYCLIN D1;
D O I
10.1002/iub.428
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
It is becoming increasingly clear that dysregulation of protein synthesis contributes to a range of diseases characterized by tissue overgrowth. These include arterial stenosis, cardiac hypertrophy, hamartomas, and cancer. The central hub for the regulation of protein synthesis is the ribosome, where the key signaling pathways downstream of RAS, MYC, and phosphatidylinositol-3-kinase (PI3K) converge to confer exquisite, coordinated control of ribosome synthesis and function. Such cooperation ensures strict regulation of protein synthesis rates and cell growth. This review will focus on the role the PI3K/AKT/mammalian target of rapamycin complex 1 (mTORC1) pathway plays in regulating ribosome function during both health and disease, its interaction with the other key growth regulatory pathways activated by RAS and MYC, and the therapeutic potential for targeting this network. (C) 2011 IUBMB IUBMB Life, 63(2): 79-85, 2011
引用
收藏
页码:79 / 85
页数:7
相关论文
共 65 条
[1]   New inhibitors of the mammalian target of rapamycin signaling pathway for cancer [J].
Albert, Sebastien ;
Serova, Maria ;
Dreyer, Chantal ;
Sablin, Marie-Paule ;
Faivre, Sandrine ;
Raymond, Eric .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (08) :919-930
[2]   Perturbations of the AKT signaling pathway in human cancer [J].
Altomare, DA ;
Testa, JR .
ONCOGENE, 2005, 24 (50) :7455-7464
[3]   An essential role for protein synthesis in oncogenic cellular transformation [J].
Bader, AG ;
Vogt, PK .
ONCOGENE, 2004, 23 (18) :3145-3150
[4]   TIF-IA, the factor mediating growth-dependent control of ribosomal RNA synthesis, is the mammalian homolog of yeast Rrn3p [J].
Bodem, J ;
Dobreva, G ;
Hoffman-Rohrer, U ;
Iben, S ;
Zentgraf, H ;
Delius, H ;
Vingron, M ;
Grummt, I .
EMBO REPORTS, 2000, 1 (02) :171-175
[5]   Increased expression of UBF is a critical determinant for rRNA synthesis and hypertrophic growth of cardiac myocytes [J].
Brandenburger, Y ;
Jenkins, A ;
Autelitano, DJ ;
Hannan, RD .
FASEB JOURNAL, 2001, 15 (09) :2051-+
[6]   Protein kinase signaling networks in cancer [J].
Brognard, John ;
Hunter, Tony .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2011, 21 (01) :4-11
[7]   Mutation of the PIK3CA gene in ovarian and breast cancer [J].
Campbell, IG ;
Russell, SE ;
Choong, DYH ;
Montgomery, KG ;
Ciavarella, ML ;
Hooi, CSF ;
Cristiano, BE ;
Pearson, RB ;
Phillips, WA .
CANCER RESEARCH, 2004, 64 (21) :7678-7681
[8]  
Campbell IG, 2005, CLIN CANCER RES, V11, P7042, DOI 10.1158/1078-0432.CCR-05-1024
[9]   Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway [J].
Carayol, Nathalie ;
Katsoulidis, Efstratios ;
Sassano, Antonella ;
Altman, Jessica K. ;
Druker, Brian J. ;
Platanias, Leonidas C. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (13) :8601-8610
[10]   Not all substrates are treated equally Implications for mTOR, rapamycin-resistance and cancer therapy [J].
Choo, Andrew Y. ;
Blenis, John .
CELL CYCLE, 2009, 8 (04) :567-572